Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H24N4O3S |
Molecular Weight | 316.42 |
Optical Activity | ( + ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NC[C@@H](O)COC1=NSN=C1N2CCOCC2
InChI
InChIKey=BLJRIMJGRPQVNF-SNVBAGLBSA-N
InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6121594Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8286 | https://www.ncbi.nlm.nih.gov/pubmed/2896241
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6121594
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8286 | https://www.ncbi.nlm.nih.gov/pubmed/2896241
(R)-Timolol is the (R)-enantiomer of non-selective Beta antagonist Timolol. (R)-Timolol is a ß-adrenergic blocking agent that binds only to nonspecific sites in the particulate fraction of the heart, lungs, and brain. (R)-Timolol is an antihypertensive agent that increases ocular blood flow and reduces intraocular pressure. (R)-Timolol is one of the impurities in commercial formulation of (S)-Timolol.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6126588 |
26.9 nM [Kd] | ||
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6126588 |
13.8 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8286
Rats were treated i.v. with 0.1 mg/kg of (R)-Timolol
Rats were treated p.o. with 1-10mg/kg of (R)-Timolol
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2896241
Rabbit eyes and heart ventricle were from New Zealand albino males, 3 to 6 months old. Chary process villae were separated carefully from any contaminating iris or ciliary body, washed once in 150 mM NaCl and homogenized (10 mg/ml) by hand in an all-glass homogenizer in 6 mM Tris maleate buffer, pH 7.4. Heart tissue was first minced and then homogenized (20-50 mg/ml). Aparticulate (P1) preparation was prepared by diluting the homogenate in 20 volumes of 6 mM Tris maleate buffer, centrifuging at 100,000 x g for 30 min, and resuspending the pellet in the initial volume of buffer used for homogenization. Kinetic constants obtained using the P1 fraction as a source of adenylate cyclase were similar to those obtained using homogenates. Inhibition (by various concentrations of an antagonist) of beta adrenergic receptor-mediated activation of adenylate cyclase activity was used to determine the inhibitory constants. IC50 values were determined utilizing 12 to 16 data points per dose-response curve. For the inhibition curves, various concentrations of antagonist were tested against a fixed concentration of (-)-isoproterenol. Stimulation in the presence of isoproterenol plus antagonist was calculated as the increase over that seen in the presence of antagonist alone.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
168613
Created by
admin on Sat Dec 16 10:07:07 GMT 2023 , Edited by admin on Sat Dec 16 10:07:07 GMT 2023
|
PRIMARY | |||
|
26839-76-9
Created by
admin on Sat Dec 16 10:07:07 GMT 2023 , Edited by admin on Sat Dec 16 10:07:07 GMT 2023
|
PRIMARY | |||
|
248-033-1
Created by
admin on Sat Dec 16 10:07:07 GMT 2023 , Edited by admin on Sat Dec 16 10:07:07 GMT 2023
|
PRIMARY | |||
|
2BG20ZUO2E
Created by
admin on Sat Dec 16 10:07:07 GMT 2023 , Edited by admin on Sat Dec 16 10:07:07 GMT 2023
|
PRIMARY | |||
|
DTXSID801318141
Created by
admin on Sat Dec 16 10:07:07 GMT 2023 , Edited by admin on Sat Dec 16 10:07:07 GMT 2023
|
PRIMARY | |||
|
39466
Created by
admin on Sat Dec 16 10:07:07 GMT 2023 , Edited by admin on Sat Dec 16 10:07:07 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD